Creo Medical - Positive Q122 trading update
Creo Medical has released a Q122 trading update and is scheduled to publish FY21 results in early May 2022. Management highlighted the increased demand for elective procedures (as well as a rise in endoscopy cases) drove strong volume growth for Creo’s Speedboat products. The month of March was particularly strong with the return of hospital visits as COVID-19 fears and restrictions dissipate. The company's integration of its recent acquisition of Aber Electronics (November 2021) further strengthens its technology platform. As a further development, in January 2022, the company signed a number of non-binding heads of terms (HoT) agreements for its SpydrBlade, Cool Plasma and MicroBlate technologies, with potential to develop into licensing agreements.Creo Medical Group is a medical device company focused on the field of surgical endoscopy, a recent development in minimally invasive surgery. Co. is focused on developing and commercializing a suite of medical devices based on its CROMA electrosurgery platform.
Edison is an investment research and advisory company, with offices in North America, Europe, the Middle East and AsiaPac. The heart of Edison is our world renowned equity research platform and deep multi-sector expertise. At Edison Investment Research, our research is widely read by international investors, advisors and stakeholders. Edison Advisors leverages our core research platform to provide differentiated services including investor relations and strategic consulting.
.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.